
Invests in therapeutics, diagnostics, tools and software for Andreessen Horowitz's Bio + Health team; earlier chief strategy, financial and product officer at Syros.
| Moderna CEO Stéphane Bancel on the Next Era of mRNA | Raising Health | 2026-09-02 | a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company | The a16z Show | 2026-02-16 | a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on LinkedIn: https://www.linkedin.com/in/vasnarasimhan/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Stay Updated: Find a16z on YouTube: YouTube Find a16z on X Find a16z on LinkedIn Listen to the a16z Show on Spotify Listen to the a16z Show on Apple Podcasts Follow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Wartime vs Peacetime: Ben Horowitz on Leadership | The a16z Show | 2026-01-02 | In this exclusive conversation from a16z’s Bio and Health BUILD Summit, founding partner Ben Horowitz sits down with general partner Jorge Conde. Originally released in August 2023, the episode covers everything from the inspiration behind Ben’s book The Hard Thing About Hard Things and how the open internet was secured, to the difference between wartime and peacetime CEOs, what it really means to scale culture, and how bio and healthcare innovation differs from other forms of technology. Ben’s Book: https://www.amazon.com/Hard-Thing-About-Things-Building/dp/0062273205 Resources: Follow Ben on Twitter: https://x.com/bhorowitz Follow Jorge on Twitter: https://x.com/jorgecondebio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. | |
| How to Build This Generation's Big Pharma Company | Raising Health | 2025-11-17 | Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.\ Timecodes: 0:00 Introduction 0:38 Why Formation Bio? Origins and Mission 1:12 The Real Bottleneck: Clinical Development 4:56 Formation Bio’s Business Model 7:50 Picking Winners: The Art and Science of Drug Selection 11:54 First-in-Class vs. Best-in-Class Strategies 14:04 Overcoming Regulatory and Market Challenges 17:26 The Stakes: Can We Approve More Drugs? 19:07 How Formation Bio Cuts Cost and Time 21:43 AI’s Role in Drug Development 25:10 The Future: From 50 to 500 Drug Approvals? 35:18 Global Competition: The Rise of China 39:28 The Path Forward: Data, Regulation, and Access 41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiu Find Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! | |
| Dyno Therapeutics: Empowering Patients with Genetic Agency | Raising Health | 2025-11-07 | For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants. Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes. Resources: Follow Eric on X: https://x.com/ekelsic Follow Jorge on X: https://x.com/JorgeCondeBio Learn more about GATC 2025: https://www.dynotx.com/gatc2025 Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! | |
| America's Autism Crisis and How AI Can Fix Science with NIH Director Jay Bhattacharya | The a16z Show | 2025-09-23 | Dr. Jay Bhattacharya is one of the country’s top medical experts and a 24-year professor of medicine at Stanford. After being censored and deplatformed during COVID for his role in opposing harsh lockdowns, he was appointed Director of the National Institutes of Health by President Trump in 2025. a16z General Partners Erik Torenberg, Vineeta Agarwala, and Jorge Conde join Dr. Bhattacharya to discuss the administration’s role in tackling the autism crisis, how to restore public trust in health authorities, how to make the NIH more dynamic and efficient, and how to streamline publishing and restore academic freedom. Timecodes: 0:00 Introduction 1:30 Autism Initiative & New Research 2:45 Drug Discoveries: Leucovorin & Tylenol Caution 4:35 Preterm Birth & Broader Health Initiatives 5:45 The Replication Crisis in Science 8:50 Reforming NIH Funding & Scientific Culture 14:00 Allocation vs. Execution at NIH 17:30 Political & Scientific Decision-Making 22:30 Addressing Life Expectancy & Chronic Disease 27:00 Supporting Early Career Investigators 34:50 Academic Freedom & Open Science 37:30 Rebuilding Public Trust in Public Health 41:00 Communicating Science Amid Uncertainty 47:50 NIH Priorities: Nutrition, Chronic Disease, AI 50:00 The Future of AI in Science & Medicine 53:30 Advice for Rising Scientists 55:00 The Role and Limits of AI in Science Resources: Find Dr. | |
| Fueling Innovation with Data with Arif Nathoo | Raising Health | 2025-05-13 | Arif Nathoo, cofounder and CEO of Komodo Health, joins Jorge Conde and Jay Rughani to explore the transformative potential of healthcare data in reshaping biotech and healthcare innovation. Arif reflects on a decade-long journey of unlocking the power of fragmented healthcare data, delving into Komodo Health’s “full-stack thesis” — a strategy that combines rich datasets, advanced analytics, and AI to enable life sciences companies, payors, and providers to make better decisions at scale. Together, the three also discuss leveraging predictive AI to identify undiagnosed patients and optimize care delivery. Arif also shares actionable advice for founders, from picking the right partner to staying steadfast in the vision. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Mastering Data with Sajith Wickramasekara | Raising Health | 2024-11-12 | In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform. Saji discusses his journey from software engineer to building Benchling and digitizing biotech workflows for industry giants like Sanofi. Together, they also talk about the increasing complexity of biology, the expanding role of AI in drug discovery, and the power of well-structured data. The 21st century isn't just the century of advanced biology—it's also the era of creating tools that supercharge scientific discovery. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| The History and Future of CAR T with Bruce Levine | Raising Health | 2024-08-06 | Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health. Bruce talks about how his time working in a lab at the Children’s Hospital of Philadelphia inspired him to work on translational therapies. Together, they also discuss barriers to access for cancer therapeutics and how the fight against cancer is progressing. Additional disclosures for Bruce include: Scientific Advisory Boards: Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, UTC Therapeutics. Scientific Advisor: Kite. Past: Akron, Vycellix Co-Founder and equity holder: Tmunity Therapeutics (acquired by Kite), Capstan Therapeutics Board of Directors: Alliance for Cancer Gene Therapy Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Protecting the Golden Age of Medicine with John Crowley | Raising Health | 2024-07-23 | 31 min | |
| Unleashing CAR T with Carl June | Raising Health | 2024-05-07 | In this episode, Carl June, MD, pioneering immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health. Together, they discuss Carl's work on CAR T, a remarkable story of the first use of CAR T in a pediatric patient, and Carl's take on where oncology treatments are headed next. Though this episode was originally published in September 2023, back when we were called Bio Eats World, we’re republishing it during this year’s ASGCT conference, where the latest advances in cell and gene therapy—like what Carl describes—are shared and discussed. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Drag & Drop Genome Editing | Raising Health | 2024-01-16 | Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health. Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people. Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Unleashing CAR T with Carl June | Raising Health | 2023-09-12 | Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health. Together, Carl and Jorge talked about Carl's pioneering work in CAR T therapy — including the terrifying moment where he thought he had accelerated one of his patient's deaths, how he started working in human immunology, and his take on where cancer treatment is headed next. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Becoming a Partnership Pioneer with Dan Nomura | Raising Health | 2023-09-05 | Dan Nomura is a distinguished professor at UC Berkeley and an Investigator at the Innovative Genomics Institute, specializing in Chemical Biology and Molecular Therapeutics. He serves as the Director of the Novartis-Berkeley Translational Chemical Biology Institute and founded Frontier Medicines and Vicinitas Therapeutics. He’s also a16z Bio+Health’s newest advisory partner. In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Wartime vs Peacetime: Ben Horowitz on Leadership | The a16z Show | 2023-08-24 | In this exclusive conversation from a16z’s Bio and Health BUILD Summit, founding partner Ben Horowitz sits down with general partner Jorge Conde. They discuss everything from the inspiration behind Ben’s book The Hard Thing About Hard Things, how the open Internet was secured, the difference between wartime and peacetime CEOs, scaling culture, and understanding how bio & healthcare differs from other forms of technology. Topics Covered: 00:00 - Introduction 02:09 - What are the most important lessons for a CEO? 08:45 - Surprising leaders in history 11:41 - Wartime CEO vs the peacetime CEO 14:54 - Cultures role 20:59 - Communication and scaling 25:39 - Culture as a moat 27:46 - The interplay between startups and incumbents 30:22 - Advice for founders on navigating AI Resources: Find Ben on Twitter: https://twitter.com/bhorowitz Find Jorge on Twitter: https://twitter.com/jorgecondebio Ben’s Book: https://www.amazon.com/Hard-Thing-About-Things-Building/dp/0062273205 Stay Updated: Find a16z on Twitter: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: https://twitter.com/stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. | |
| Adapting Biopharma to AI with Greg Meyers | Raising Health | 2023-06-01 | Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde. Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| mRNA for Flu Vaccine? AI Protein-Folding Goes Open Source | 16 Minutes News by a16z | 2021-08-02 | In today’s episode we have two short segments, both on bioscience topics: [0:00] Moderna has started clinical trials for a flu vaccine, called mRNA-1010, that is based on the same mRNA technology that Moderna and Pfizer used for their COVID vaccines, and that several other companies including Sanofi and Glaxo all are actively working on for the influenza use case. Our experts are general partners Vineeta Agarwala and Jorge Conde of the a16z bio team, who have joined us on many of our vaccine-related episodes, which you can find at a16z.com/vaccines. They discuss what comes next for the clinical trials of this mRNA-based flu vaccines, why companies aren't planning to use the faster and more-targeted mRNA technology for COVID's Delta variant, and how mRNA vaccines will change not only our approach to flu shots but to other respiratory viruses. [9:53] Google’s DeepMind AlphaFold, in partnership with the European Molecular Biology Laboratory, is publicly sharing its entire protein structure database -- with predicted protein structure models for ~20,000 proteins expressed by the human genome -- meaning that all its data will be freely and openly available to the scientific community. (We previously discussed DeepMind's AlphaFold protein-folding AI on this show in episode #48.) General partner Vijay Pande of the a16z bio team helps us answer the question: Why does it matter that a huge database of very accurate predicted protein structures is now freely available? | |
| Opioid Crisis - How, Who, and Tech | 16 Minutes News by a16z | 2021-07-26 | Given recent news of drug company settlements, calls to action, policy moves, and more, this episode is a rerun of one of our very early explainers (episode #4 of 16 Minutes, 2019) on the opioid crisis. Bio experts and a16z general partners Jorge Conde and Vijay Pande discuss on 16 Minutes (our shortform show where we discuss the headlines, tease apart what's hype' what's real, and where we are on the long arc of innovation) with host Sonal Chokshi: how opioids work; the questions around who's to blame; and other directions for managing pain. Where could tech come in, even with the broader social, cultural, and structural context involved here? original episode: https://a16z.com/2019/08/04/16mins-news-opioid-crisis-dea-database/ | |
| a16z Bio + Health #12: Talking Price Transparency and Patient Engagement with Florian Otto | a16z Live | 2021-05-05 | On this episode of the a16z Bio Clubhouse Show, a16z general partners Julie Yoo and Jorge Conde, managing partner Scott Kupor, and market development partner Venkat Mocherla talk to guest Florian Otto, cofounder and CEO of Cedar. The conversation covers how to improve two of the trickiest aspect of healthcare: price transparency and patient engagement. | |
| a16z Bio + Health #11: The Digital Health OGs | a16z Live | 2021-04-28 | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, and Jorge Conde talk to guests Sean Duffy, cofounder and CEO of Omada Health, Karan Singh, cofounder and COO of Ginger, and Chris Hogg, a serial entrepreneur in the digital health space. The conversation covers go-to-market strategies, financing and aligning incentives, the struggles of interoperability (or lack thereof), and what it is like to build today versus in the early years. | |
| a16z Bio + Health #8: How to Innovate within Biopharma with Jay Bradner | a16z Live | 2021-04-01 | On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guest Jay Bradner, President of the Novartis Institute of Biomedical Research (NIBR). The conversation covers the challenges of translating basic research into a clinical application, the state of innovation in therapeutics, and the transition from drug hunting to drug farming. | |
| a16z Bio + Health #7: The Power of Patient Data with Anne Wojcicki | a16z Live | 2021-03-30 | 37 min | |
| a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside | a16z Live | 2021-03-18 | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences. The conversation covers the growing role of artificial intelligence and machine learning in drug development and specifically in biologics and protein therapeutics. | |
| a16z Bio + Health #5: From COVID to Consumerism & the Future of Virtual First Care with Stephen Klasko | a16z Live | 2021-03-13 | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Julie Yoo, Vineeta Agarwala, Jorge Conde, and Vijay Pande, along with market development partner Venkat Mocherla, talk to guest Dr. Stephen Klasko, the president of Thomas Jefferson University and CEO of Jefferson Health about transforming the US healthcare system. | |
| a16z Bio + Health #4: The History and Future of Genome Engineering with George Church | a16z Live | 2021-03-10 | On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande, along with a16z cofounder Marc Andreessen, talk to guest Dr. George Church of Harvard University about past, future, and power of genome engineering. | |
| a16z Bio + Health #3: Metabolic Health with Casey Means | a16z Live | 2021-03-09 | On this episode of the new a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Jeff Jordan, and Vijay Pande, talk to guest Dr. Casey Means, co-founder of Levels Health, about metabolism and metabolic health. | |
| a16z Bio + Health #2: Digital Diagnostics with Gaurav Singal | a16z Live | 2021-02-26 | On this episode of the new a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Vijay Pande, talk to guest Dr. Gaurav Singal about the future of digital diagnostics: what are they, who stands to benefit from them, and critically, who pays. | |
| What to Know about Those Vaccines | The a16z Show | 2020-11-20 | A vaccine for COVID seems to be (almost) here… or is it? What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement last week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19 -- and relatedly, the most recent news around Moderna's vaccine candidate? Of course, this was just the first interim efficacy analysis — so how close or far are we? What’s the significance of the readout and case numbers? How do we put all this in context of all the other (458!) programs in development? And how much should/ shouldn’t we read into the news, given the buzzy excitement and penchant for evaluating "science via press release"? a16z bio general partners Vineeta Agarwala and Jorge Conde recently broke it all down in conversation with Sonal Chokshi on our show 16 Minutes: the math, the science, and the practical considerations — from “vaccine efficacy” vs. efficiency, from cold chains to distribution, from patients to the system… as well as why mRNA matters in the present future of vaccines. | |
| Covid Vaccine! Beyond Science via Press Release | 16 Minutes News by a16z | 2020-11-14 | A vaccine for COVID seems to be (almost) here... or is it? What's hype/ what's real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19? Of course, this was just the first interim efficacy analysis -- so how close or far are we? What's the significance of the readout and case numbers? How do we put this (and related approaches, like Moderna's) in context of all the other (458!) programs in development? And how much should/ shouldn't we read into this news? After all, it's "difficult to evaluate science via press release", as some say. So in this episode of 16 Minutes with a16z bio general partners Vineeta Agarwala and Jorge Conde in conversation with Sonal Chokshi, we break it all down: the math, the science, and the practical considerations -- from "vaccine efficacy" vs. efficiency, from cold chains to distribution, from patients to the system... as well as from the past, to present future of, vaccines. references and readings cited in this episode: BioCentury.com/coronavirus , COVID-19 therapies and vaccines: Clinical; COVID-19 therapies and vaccines: Preclinical; COVID-19 Clinical Trial Dashboard, November 2020 " Vaccine Efficacy 101: A biostatistician's primer ", Natalie E. Dean, Twitter, September 2020 " Understanding COVID-19 vaccine efficacy ", Marc Lipsitch and Natalie E. | |
| A Nobel for CRISPR! When, Who, How, What Now | 16 Minutes News by a16z | 2020-10-10 | "It's CRISPR!" This week, the Nobel Prize in Chemistry was awarded to scientists Emmanuelle Charpentier and Jennifer Doudna (also an a16z co-founder, of Scribe Therapeutics ), for the development of the CRISPR/Cas9 method for genome editing -- a technology that's "had a revolutionary impact on the life sciences, is contributing to new cancer therapies, and may make the dream of curing inherited diseases come true". While many describe this technology as "genetic scissors", one of the sharpest tools , is that analogy too limited for describing the true power and potential of CRISPR as a gene-editing platform ? And while the time between (unexpected) discovery to practice to award has been less than a decade -- further confirming that we're in the new century of biology! -- at what point does such discovery become engineering, that is, innovations we can use and systematize and scale (much like transistors )? In this special episode of 16 Minutes, a16z general partners Vijay Pande and Jorge Conde, in conversation with Sonal Chokshi, examine the long arc and narrative of CRISPR, both backwards and forward; tease apart what's hype/ what's real in terms of where we really are, in practice; and... celebrate the incredible milestone this is. It's CRISPR!, and much more... | |
| On Vaccines and Vaccinology, in COVID and Beyond | The a16z Show | 2020-08-14 | WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will and won’t be compromised here, and where do new technologies -- like mRNA or messenger RNA vaccines -- come in? Where will vaccines likely be distributed first, who will and won't get them initially, both across populations... and nations? Rajeev Venkayya , president of the Global Vaccine Business Unit at Takeda Pharmaceutical Company and former White House Special Assistant to the President for Biodefense (where, among other things, he was the principal author of the National Strategy for Pandemic Influenza ) joins this special deep-dive episode of the a16z Podcast, in conversation with general partner Jorge Conde to discuss all things vaccines. Including where does manufacturing and scale-up come in -- is "plug and play" really here? -- and by the way, why have we traditionally used eggs in growing vaccines? Where and how can startups and others participate in vaccine development, given how competitive, time-consuming, capital intensive, and risky it is to develop (and sell) them? Can we decouple the question of how we reopen schools with when we have a vaccine? And how do we maintain not just safety and efficacy of vaccines but trust and transparency when it comes to mis/information? We may actually see the emergence of a "Neo Anti-Vaxxer" thanks to the rush... | |
| CRISPR for Covid Testing and FDA EUAs | 16 Minutes News by a16z | 2020-05-17 | As calls for better, faster, cheaper, portable testing for COVID-19 disease are heard around the world -- given the important role of test-trace-isolate in re-opening the economy! -- the FDA recently issued an Emergency Use Authorization (EUA) for a CRISPR-based diagnostic. It's the first authorized use of CRISPR technology for an infectious disease test. So we discuss this topic in this week's episode of 16 Minutes -- our show where we cover the news headlines, tease apart what's hype/what's real from our vantage point in tech, and share where we are on the overall arc of various trends -- covering: where are we with testing for COVID overall given the taxonomy of what's already here and what's coming; where are we with CRISPR technology, given that this is the one of the first times it's being used for diagnostics vs. therapeutics (and that clinical trials are only coming of age there now; how does this work, and how does this type of CRISPR compare to the PCR approach for testing; and how do EUAs and more play out given past policy debates and discussions of CRISPR and gene editing ...with a16z general partner Jorge Conde and bio deal team partner Andy Tran, in conversation with Sonal Chokshi. On 16 Minutes, we also offer frameworks for thinking about the topics covered, so we also discuss: the tradeoffs between specificity and sensitivity when it comes to testing, especially when there's a big difference in false positives in testing for the disease vs. | |
| Undruggable Drugs | The a16z Show | 2020-05-06 | In this episode of the a16z Podcast, we take a deep dive into the world of drug development—specifically "undruggable drugs": a category of protein, protein family or even piece of RNA that’s so difficult to target that many researchers don’t even want to touch it. Jay Bradner, President of the Novartis Institute for BioMedical Research, shares with a16z General Partners Jorge Conde and Vijay Pande, and a16z's Hanne Tidnam, all the new tools, technologies and breakthroughs which are causing the science of therapeutics to explode in some of these areas where it's been incredibly difficult (even impossible) in the past. From molecular glues to cell and gene therapies, Bradner shares the behind-the-scenes science stories of what it really takes to make a new drug that shatters the category of an "undruggable" target. Stay Updated: Find a16z on YouTube: YouTube Find a16z on X Find a16z on LinkedIn Listen to the a16z Show on Spotify Listen to the a16z Show on Apple Podcasts Follow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. | |
| When Bad Policy = Bad Business Models = Bad Public Health | The a16z Show | 2020-04-16 | with @JorgeCondeBio, @julesyoo, and @omnivorousread In some ways, the coronavirus feels like it came out of nowhere—a kind of Black Swan event. But at the same time, it's been exposing a lot of the fundamental flaws in our healthcare system that now feel like a perfect storm coming together... and have hurt our ability to address the problem that we should really have seen coming. In this episode, a16z General Partners Jorge Conde and Julie Yoo talk with Hanne Tidnam about some of those big forces and dynamics in the healthcare system, at the intersection of business, policy, and public health: how in healthcare like perhaps nowhere else, broken policy can lead to broken business models that, in the wrong circumstances, can then lead major failures in public health like the one we’re seeing today; where we’ve seen this before, in the markets of vaccines, antibiotics, and diagnostics; and what should be different next time, so that when a new pandemic hits we aren’t facing another perfect storm. Stay Updated: Find a16z on YouTube: YouTube Find a16z on X Find a16z on LinkedIn Listen to the a16z Show on Spotify Listen to the a16z Show on Apple Podcasts Follow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. | |
| Building the First CAR T Company | The a16z Show | 2020-02-07 | with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousread CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn't just one new medicine, it's an entirely new therapeutic tool—and a total paradigm shift from most traditional medicines we've seen before. Tmunity CEO Usman "Oz" Azam was previously the head of Cell and Gene Therapies at Novartis, in many ways the first CAR T company and the team brought us blood cancer CAR T-cell therapy Kymriah—the first cell-based gene therapy to be approved in the US. In this conversation, Azam discusses with a16z's general partner Jorge Conde and Hanne Tidnam what CAR T therapy really is and how it all works. The conversation begins with the “patient and cell journey” of this treatment and how this medicine is developed, manufactured, delivered to patients; why exactly it's so different traditional medicines; what it will take to make these new medicines work on more kinds of cancer, scale to more patients, and cost less; and finally, what company building lessons can be learned from building the first CAR T company of its kind from the ground up. This episode was recorded at the annual a16z Summit. | |
| On Pharma Trends and Big Company Innovation | The a16z Show | 2020-01-11 | How does the world’s largest producer of medicines in terms of volume balance the science and the business of innovation? How does an enterprise at such vast scale make decisions about what to build vs. buy, especially given the fast pace of science today? How does it balance attitudes between “not invented here” and “not invented yet”? Vas Narasimhan, CEO of Novartis, sat down with a16z bio general partners Jorge Conde and Vijay Pande, and editor in chief Sonal Chokshi, during the JP Morgan Healthcare Conference around this time last year, to discuss the latest trends in therapeutics; go to market and why both big companies and bio startups need to get market value signals (not just approvals!) from payers earlier in the process; clinical trials, talent, leadership, and more in this rerun of the a16z Podcast. image: Global Panorama / Flickr Stay Updated: Find a16z on YouTube: YouTube Find a16z on X Find a16z on LinkedIn Listen to the a16z Show on Spotify Listen to the a16z Show on Apple Podcasts Follow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. | |
| Personal Genomics - Hype vs Reality (#18) | 16 Minutes News by a16z | 2020-01-06 | For our first episode of 2020 -- #18 of our show 16 Minutes , where we cover recent headlines, the a16z way, from our vantage point in tech, and especially what's hype/ what's real -- we do one of our special deep-dive episodes on a single topic: personal genomics. It’s a turn of the decade — and January-appropriate! — look backward/ look forward given recent and past retrospective and prospective pieces in the media on the promise, and perils, of the ability to sequence one’s DNA and what it means for personalized medicine, criminal investigations, privacy, and so on. Our a16z expert for this episode is general partner Jorge Conde , who has a long history in the space, in conversation with host Sonal Chokshi. They cover everything from where genealogy databases and large datasets come in to fetal testing, multi-omics, and much more spanning past, present, and future. | |
| The Opioid Crisis (#4) | 16 Minutes News by a16z | 2019-08-04 | This is episode #4 of our new show, 16 Minutes, where we quickly cover recent headlines of the week, the a16z way -- why they're in the news; why they matter from our vantage point in tech -- and share our experts' views on these trends as well. This week we do a short but deep dive on the opioid crisis, given recent data around where and who was behind the manufacturing and distribution of specific opioids: How do opioids work, why these drugs? Who's to blame? What are other directions for managing pain -- and where could tech come in, even with the broader social, cultural, and structural context involved? Our a16z experts in this episode are a16z bio general partners Jorge Conde and Vijay Pande, in conversation with host Sonal Chokshi. | |
| Mobile Malware, Drug Pricing (#2) | 16 Minutes News by a16z | 2019-07-28 | This is episode #2 of our new show, 16 Minutes, where we quickly cover recent headlines of the week, the a16z way -- why they're in the news; why they matter from our vantage point in tech -- and share our experts' views on these trends as well. This week we cover, with the following a16z experts: mobile malware and a recent report of a new kind in the wild and security in a post-perimeter world -- with a16z general partner Martin Casado; drug pricing given recent proposals on the table, sharing a lay of the land for why drug pricing is so damn hard, what is a medicine , and where tech comes in -- with a16z bio general partner Jorge Conde and market dev partner Jay Rughani; ...hosted by Sonal Chokshi. *The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. | |
| Inside Moderna’s Biggest mRNA Test Since COVID | The a16z Show | |||
| Novartis CEO on the Future of Medicine | a16z Full Interview | a16z Bio & Health | |||
| Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde | The a16z Show | |||
| a16z Podcast | What's in the Water at the George Church Lab? | The a16z Show |
aa16z Bio + Health #7: The Power of Patient Data with Anne Wojcickia16z Live · 2021-03-30
TInside Moderna’s Biggest mRNA Test Since COVIDThe a16z Show
aNovartis CEO on the Future of Medicine | a16z Full Interviewa16z Bio & Health
TBig Ideas in 2024: Programming Medicine’s Final Frontier with Jorge CondeThe a16z Show
Ta16z Podcast | What's in the Water at the George Church Lab?The a16z Show